Bris­tol My­ers flags an­oth­er PhI­II suc­cess for one of their top block­buster prospects, clear­ing a path to the FDA

Re­searchers for Bris­tol My­ers Squibb say they have cleared the sec­ond big Phase III hur­dle for their block­buster pso­ri­a­sis con­tender deu­cravac­i­tinib, clear­ing the path to an FDA fil­ing with more da­ta to prove the oral drug’s su­pe­ri­or­i­ty to Ote­zla.

Once again, there are no hard da­ta to re­port, as the Bris­tol My­ers team is hold­ing the num­bers for a sci­en­tif­ic con­fer­ence, but com­pa­ny CMO Samit Hi­rawat says that they once again nailed down sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful da­ta to demon­strate their drug came through on two key sec­on­daries, with 6 mg once dai­ly prov­ing su­pe­ri­or to Ote­zla (apremi­last) in the pro­por­tion of pa­tients reach­ing PASI 75 and sP­GA 0/1 at Week 16. The co-pri­ma­ry end­points of su­pe­ri­or­i­ty over a place­bo — a nec­es­sary though not par­tic­u­lar­ly tough ob­jec­tive — were al­so met.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER